A mlodipine is a long acting dihydropyridine Ca 2ϩ antagonist with vascular selectivity. In vitro studies have suggested that the dihydropyridine Ca 2ϩ antagonists act as antioxidants by directly quenching several radical species. 1, 2 The antioxidant activity of these Ca 2ϩ antagonists probably contributes to their Ca 2ϩ blocking and antihypertensive effects. 3 Hypertension induced by oxidative stress has been demonstrated in normal rats after glutathione (GSH) depletion. 4 -7 The pathogenesis of hypertension due to increased reactive oxygen species (ROS) has been attributed to endothelial dysfunction caused by inactivation of nitric oxide, 8 generation of vasoconstrictive isoprostanes from arachidonic acid peroxidation, 9 and a direct vasopressor or diminished vasodilator activity. 10 On the other hand, levels of free radical scavengers such as vitamin E, 11 glutathione, 12 and superoxide dismutase 13 have been reported to be depressed in hypertensive patients and experimental animals. Glutathione is the most abundant nonprotein intracellular thiol, with multiple roles as an antioxidant agent.
14 It functions as a scavenger of ROS and peroxynitrite. Induction of oxidative stress by GSH depletion has been demonstrated in rats after administration of buthionine sulfoximine (BSO), a selective inhibitor of ␥-glutamyl cysteine synthetase, an enzyme in the GSH biosynthetic pathway. 15 This study investigates the cardiovascular effects of the dihydropyridine Ca 2ϩ antagonist, amlodipine, on oxidative stress induced by GSH depletion and its effect on endothelium-derived factors and associated second-messenger signaling mechanisms, specifically, the changes in aortic cyclic adenosine monophosphate (cAMP) and cyclic guanosine monophosphate (cGMP).
Methods

Experimental Design
Male Sprague-Dawley rats (Harlan Sprague-Dawley, Indianapolis, IN), 4 to 5 weeks of age, were grouped five per cage in the animal facility that has 12-h light/dark cycles with the temperature controlled at 21°to 23°C. Rodent Lab Chow (Purina Mills, St. Louis, MO) and water were made available ad libitum. After 1 week of acclimatization, the animals were individually housed and divided into (n ϭ 6) receiving the following in the drinking water: 1) BSO, 30 mmol/L/day; 2) amlodipine, 3 mg/kg/day; 3) BSO ϩ amlodipine; or 4) regular tap water. Before treatment and after 1 wk of treatment, indirect blood pressure (BP) and heart rate were measured. After these measurements, each animal was anesthetized (using 70 mg/kg ketamine and 10 mg/kg xylazine, intramuscularly), and the carotid and jugular vein were cannulated using PE 50 tubing containing heparin (20 IU/mL) in 0.9% NaCl. The cannulae were externalized in the posterior cervical region and occluded with a metal plug, and flushed with heparinized saline every 12 h.
Indirect BP Measurement in Conscious Rats
Tail-cuff plethysmography (Rat Tail Blood Pressure Monitor and Universal Oscillograph; Harvard Apparatus, Holliston, MA) was used to measure indirect BP. Heart rate was measured from the arterial pulse wave at the same time.
Collection and Storage of Blood Samples
Blood samples for plasma nitric oxide, thromboxane, and prostacyclin measurements were collected by free flow via the polyethylene cannula in the carotid artery into heparinized and indomethacin (100 mmol/L)-rinsed (for prostaglandin samples) tubes.
To assess plasma glutathione and isoprostane concentrations, blood samples were withdrawn via cardiac puncture from all animals (under ketamine/xylazine anesthesia administered intravenously) before they were killed; the samples were centrifuged at 3000 g for 25 min at 4°C. For the isoprostane assay, butylated hydroxytoluene was added to 1.0 mL of plasma to give a final concentration of 0.005% (v/v); aliquots were frozen and stored at Ϫ80°C until assayed. For the glutathione assay, 1.0 mL of plasma was combined with 1.0 mL of metaphosphoric acid, incubated for 5 min at room temperature, and then centrifuged at 3000 g for 3 min. The aliquots of the supernatant were collected, frozen, and stored at Ϫ80°C until assayed.
Tissue Harvesting for in Vitro Studies
Immediately after cardiac puncture, the heart and the kidneys were harvested, frozen in liquid nitrogen, and stored at Ϫ80°C. The aortic arch was put into HEPES-buffered Earl"s balanced salt solution (EBSS; Sigma Chemical, St. Louis, MO) containing 100 mol/L indomethacin (a nonselective cyclooxygenase inhibitor) on ice before cAMP and cGMP incubations.
Total Plasma, Heart, and Kidney Glutathione Assay
Before homogenization, heart and kidney tissues were mixed 1:1.5 (w/v) with cold phosphate buffered saline. After centrifugation (3500 g for 30 min at 4°C), the supernatant was collected and frozen at Ϫ80°C until assayed. Protein was determined by the BioRad method. 16 Total GSH levels in plasma, heart, and kidney were measured by HPLC after derivatization according to the protocols of Abukhalaf et al. After purification according to the manufacturer's instructions, plasma levels (pg/mL) of prostacyclin (as 6-keto-PGF 1␣ ), thromboxane A 2 (as TXB 2 ), and total 8-isoprostane (free plus esterified in lipoproteins) were measured using enzyme immunoassay kits (Cayman Chemical, Ann Arbor, MI). Plasma nitric oxide (as nitrates ϩ nitrites) levels (mol/L) were quantitated by a colorimetric microplate assay kit that uses the Greiss reagent (Cayman Chemical, Ann Arbor, MI).
Determination of Aortic Cyclic Guanosine-Monophosphate and Cyclic Adenosine Monophosphate
Aortic tissue pieces 7 mm in length were incubated for 30 min in HEPES-buffered EBSS containing 100 mol/L indomethacin at 37°C. After 20 min in the presence of 100 mol/L zaprinast (a cyclic guanosine-monophosphate [cGMP] phosphodiesterase inhibitor), the tissue was frozen in liquid nitrogen and stored at Ϫ80°C. After deproteinization, cGMP was determined by enzyme immunoassay (Cayman Chemical) and expressed as fmoL cGMP/mg protein. For cyclic adenosine monophosphate (cAMP), the protocol was identical to that of cGMP, except that 100 mol/L isobutylmethylxanthine replaced 100 mol/L zaprinast, and a cAMP enzyme immunoassay kit was used (Cayman Chemical).
Statistical Analysis
Values are reported as mean Ϯ standard error (SEM), where n refers to the number of rats used. Statistical significance (P Ͻ .05) was evaluated using either the Student t test or, for multiple groups, analysis of variance followed by the Tukey-Kramer multiple comparison test.
Results
Heart Rate and BP
Administration of BSO for 1 week increased systolic BP, whereas treatment with amlodipine alone for the same period did not significantly alter BP. When combined with BSO, amlodipine attenuated the BSO-induced elevation in BP, without altering heart rate ( Fig. 1 ).
Plasma and Tissue Total Glutathione
The BSO-treated animals exhibited reductions in total glutathione (GSH) in plasma, heart, and kidney. Amlodipine alone did not significantly alter GSH levels in the plasma and tissues. When BSO and amlodipine were administered together, there was no significant alteration of the BSO-induced reduction in the plasma, kidney, and heart GSH levels (Fig. 2) .
Plasma Levels of Total 8-Isoprostane and Thromboxane B 2
As shown in Fig. 3 , BSO elevated plasma total 8-isoprostane and thromboxane B 2. Amlodipine alone reduced plasma total 8-isoprostane and thromboxane B 2 and reversed the BSO-induced effect.
Plasma Levels of Nitric Oxide and Prostacyclin
As shown in Fig. 4 , amlodipine elevated plasma NO, but this effect was blunted in the presence of BSO. Plasma prostacyclin was reduced by BSO, both alone and in combination with amlodipine.
Aortic Tissue cAMP and cGMP Levels
Treatment with BSO reduced aortic cAMP and there was a tendency for decreased levels of cGMP. Amlodipine alone raised aortic levels of both cAMP and cGMP. When administered concurrently with BSO, amlodipine prevented the reductions in cAMP and cGMP induced by BSO (Fig. 5) .
FIG. 1. Effect of buthionine-sulfoximine (BSO) and amlodipine (AMLOD) on systolic blood pressure (A) and heart rate (B) in
Sprague-Dawley rats. Data are presented as mean Ϯ SEM for six animals per group. Significant differences (P Ͻ .05) are denoted by: an asterisk (*) for all comparisons with the control animals; a plus (ϩ) for amlodipine versus BSO; and a trident () for BSO ϩ amlodipine versus BSO.
FIG. 2. Effect of buthionine-sulfoximine (BSO) and amlodipine (AMLOD) on plasma (A), heart (B)
, and kidney (C) glutathione (GSH) in Sprague-Dawley rats. Data are presented as mean Ϯ SEM for six animals per group. Significant differences (P Ͻ .05) are denoted by an asterisk (*) for all comparisons with the control and by a diamond (ࡗ) for BSO ϩ amlodipine versus amlodipine.
Discussion
The aim of this study was to evaluate the role of endothelium-derived factors, along with their associated signal transduction second messengers, in the antioxidant and antihypertensive effect of amlodipine, a dihydropyridine calcium channel blocker. Several studies have demonstrated that amlodipine displays antioxidant and cytoprotective activities against free radical-mediated vascular endothelial injury both in vivo and in vitro. 18 -20 In these experiments, oxidative stress was induced by the administration of BSO, which caused significant reductions in GSH levels in the plasma, heart, and kidney after 1 week. This pattern of change is consistent with previous studies that demonstrated the GSH-reducing effect of BSO and its interorgan translocation, turnover, and metabolism. 21 The reduction in GSH was associated with a significant increase in BP. Likewise, Vaziri et al demonstrated that administration of BSO caused GSH depletion, oxidative stress, and severe hypertension in normotensive rats. 4 In addition, BSO elevated plasma 8-isoprostane, a prostaglandin-like product formed by free radical peroxidation of arachidonic acid in membranes, which represents a reliable and specific in vivo marker of oxidative stress and lipid peroxidation. 22, 23 Amlodipine did not significantly alter GSH levels, but it did decrease plasma isoprostane and attenuated the BSO-induced effect. The effect of amlodipine on GSH metabolism is not well understood. Studies that examined the effects of other calcium antagonists including nicardipine, nifedipine, verapamil, and diltiazem on free radical injury in cultured endothelial cells reported that the protective mechanisms of calcium channel blockers against free radical injury may be mediated by their lipid antiperoxidative activities, which prevent the glutathione decrease induced by oxidant stress. 24 Consistent with the BP data, administration of BSO significantly altered the levels of endothelium-derived factors, evidenced by elevations in thromboxane A 2 and reductions in prostacyclin and nitric oxide. Amlodipine reduced plasma TXA 2 and significantly attenuated the increases induced by BSO. It has been demonstrated in spontaneously hypertensive rats that oxygen-derived thromboxane A 2 and prostaglandin H 2 release in smooth muscles causes free radical-induced vasoconstriction in the rat aorta. 25 An imbalance between thromboxane and prostacyclin has been demonstrated in oxidative stress, in that lipid peroxides activate the cyclooxygenase enzyme to increase thromboxane synthesis while at the same time inhibiting prostacyclin synthase to decrease prostacyclin synthesis. 26 In this study, we found that calcium channel blockade with amlodipine prevented oxidative stress-induced impairment of prostacyclin production in vivo, which is consistent with previous in vitro studies using rat aortic smooth muscle cells. 27 Consistent with the prostacyclin data, amlodipine raised cAMP and attenuated the reductions on cAMP induced by BSO. Cyclic AMP is known to act as a second messenger for vasorelaxation by hyperpolarization and may provide an explanation for the PGI 2 mechanism of action on reducing BP. 28 Amlodipine significantly elevated plasma NO accompanied by elevation of cyclic GMP levels in the aorta. These results suggest that the decrease in TXA 2 and increase in prostacyclin formation by amlodipine may be associated with the release of NO. It is known that nitric oxide diffuses out of endothelial cells, where it is synthesized, and stimulates guanylate cyclase in vascular smooth muscle cells, causing vascular relaxation. 29 Several studies have shown that amlodipine enhances NO production via a kinin-dependent mechanism involving either altered local production or activity of kinins. 30 -32 During oxidative stress, nitric oxide and superoxide react to form peroxynitrite, a potent cytotoxic oxidant, thus reducing the bioavailability of NO. 33 It has also been shown that, by inactivation of NO, superoxide production appears to be an essential mechanism for endothelial dysfunction. 34 Treatment with amlodipine alone increased plasma levels of nitric oxide; however, in the presence of BSO this effect was blocked, implying that oxidative stress may impair the beneficial effect of amlodipine in terms of nitric oxide availability. Consistently, it has been demonstrated that in vivo thiol depletion results in endothelial dysfunction and a reduced receptor-mediated vascular relaxation. This effect is caused by reduced endothelial NO formation. 35 Generally, oxidant stress has been shown to regulate both nitric oxide and prostacyclin synthase, because peroxynitrite formed by simultaneous generation of nitric oxide and superoxide selectively inhibit prostacyclin synthase. 36 Hink et al also demonstrated that vascular peroxynitrite formation inhibits the activity of prostacyclin synthase as well as NO and cGMP signaling, which may contribute to vascular dysfunction. 37 In conclusion, these findings suggest that amlodipine attenuates BSO-induced hypertension, which appears to be mediated in part by the prostanoid endothelium-derived factors and nitric oxide.
